ADVFN US – Market Content Editor
-
Johnson & Johnson introduces VARIPULSE Pro in Europe after CE Mark clearance
Johnson & Johnson (NYSE:JNJ) said it has launched the VARIPULSE Pro system in Europe after receiving CE Mark approval. The device expands the company’s pulsed field ablation (PFA) offerings used in the treatment of cardiac arrhythmias. VARIPULSE Pro incorporates a pulse sequence designed to operate at lower temperatures while delivering ablation up to five times…
-
Halozyme signs licensing deal with Vertex for drug delivery technology
Halozyme Therapeutics (NASDAQ:HALO) said its subsidiary has entered into an exclusive collaboration and licensing agreement with Vertex Pharmaceuticals (NASDAQ:VRTX) covering the use of Halozyme’s Hypercon drug delivery technology. Under the terms of the agreement, Vertex has obtained rights to use the Hypercon microparticle platform for up to three drug targets. The technology is designed to…
-
Mach Natural Resources shares drop after secondary unit offering
Mach Natural Resources LP (NYSE:MNR) shares fell about 7% on Tuesday after the company disclosed the pricing of a secondary public offering of its common units. The partnership said that selling unitholders Vepu Inc., Simlog Inc. and Sabinal Energy Operating, LLC priced an underwritten offering of 9,000,000 common units at $13.05 per unit. Mach’s units…
-
Organogenesis shares jump 20% following positive clinical trial results
Organogenesis Holdings Inc. (NASDAQ:ORGO) shares surged about 20% on Tuesday after the company reported that its PuraPly AM treatment met the primary endpoint in a randomized controlled trial targeting diabetic foot ulcers. The prospective multi-center study involved 170 patients and found that PuraPly AM used alongside standard care achieved statistically significant wound closure rates at…
-
Paysafe introduces crypto payment option for U.S. iGaming operators
Paysafe (NYSE:PSFE) said it has launched a new cryptocurrency payment solution called Pay with Crypto aimed at iGaming operators and daily fantasy sports platforms in the United States. The service, developed in partnership with MoonPay, allows players to fund their accounts using stablecoins or other cryptocurrencies in jurisdictions where such payments are permitted. Through the…
-
Fox partners with Kalshi to bring prediction market data to its platforms
Fox Corporation (NASDAQ:FOX) said it has entered into an agreement with prediction market platform Kalshi to integrate market-based forecasting data across its media properties, including Fox News Channel, Fox Business Network, Fox Weather and the Fox One streaming service. Under the sponsored collaboration, Kalshi’s real-time prediction market data will be incorporated into Fox’s television broadcasts…
-
Serve Robotics showcases AI conversational robot at NVIDIA GTC
Serve Robotics Inc. (NASDAQ:SERV) unveiled “Maggie,” its first conversational AI-powered robot, during a demonstration at NVIDIA GTC 2026. The robot is designed to communicate with people in real time while operating in public environments. “We’re building robots that don’t just move through the world, but interact with it,” said Ali Kashani, CEO and co-founder of…
-
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition
Artivion Inc. (NYSE:AORT) said the U.S. Food and Drug Administration has approved the premarket application for the NEXUS Aortic Arch System, a device developed by its partner Endospan Ltd. The regulatory clearance gives Artivion the option to acquire Endospan within a 90-day window. The company has arranged a $150 million delayed-draw term loan to help…
-
AC Immune revises collaboration with Eli Lilly on tau-targeting Alzheimer’s therapy
AC Immune SA (NASDAQ:ACIU) said it has amended its 2018 licensing and collaboration agreement with Eli Lilly and Company (NYSE:LLY) focused on developing small-molecule tau aggregation inhibitors for Alzheimer’s disease and other neurodegenerative disorders. As part of the revised terms, AC Immune will receive an upfront payment of CHF10 million and an additional milestone payment…
-
TransCode Therapeutics signs financing deal worth up to $20 million
TransCode Therapeutics Inc. (NASDAQ:RNAZ) said it has secured a financing agreement with an institutional healthcare investor that could provide the company with up to $20 million in funding. The arrangement includes up to $6 million in prepaid advances, along with a three-year Standby Equity Purchase Agreement that allows TransCode to sell as much as $14…